ProfessionalLive ClassesNo New Dates

Mindfulness Based Stress Reduction for Psychedelic Therapists

The Mindfulness Based Stress Reduction for Psychedelic Therapists course offers a comprehensive curriculum for developing mindfulness practices in support of personal and professional growth for Psychedelic Therapists.

Provider

Fluence

English

Schedule

6 Hours

Enrollment

$450

Course Overview

The Mindfulness Based Stress Reduction (MBSR) for Psychedelic Therapists course offers a comprehensive curriculum for developing mindfulness practices in support of personal and professional growth for Psychedelic Therapists. Based on the teachings of Jon Kabat-Zinn, Ph.D., the program integrates mindfulness meditation and mindful hatha yoga to provide a structured path for reducing stress and enhancing well-being.

The course objectives include familiarizing participants with the essential aspects of mindfulness relating to stress reduction, coping with pain and illness, and enhancing well-being. Participants will also learn to differentiate MBSR from relaxation techniques, identify three types of focused practices, and describe the benefits of open awareness or choiceless awareness meditation techniques.

By the end of the course, participants will be equipped with the skills to apply mindfulness in social interactions, understand the difference between stress reactivity and response, and educate patients and their families about the benefits of mindfulness-based programs.

This course is also part of the KAP and PHRI certification programs. This course is given each quarter.

Who is this for?

Psychedelic therapists and integration therapists

About the Provider

Fluence is a psychedelic therapy education company co-founded by psychologists Dr. Ingmar Gorman and Dr. Elizabeth Nielson, offering continuing education courses and a Certificate in Psychedelic Therapy and Integration for licensed therapists and advanced graduate students. Having trained 8,000+ clinicians, Fluence draws on its founders' direct experience in FDA-approved Phase 3 clinical trials of MDMA- and psilocybin-assisted therapies.

Related Courses

View all courses